Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)

v3.24.1.u1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
Balance at the beginning (in shares) at Dec. 31, 2022   145,204,974      
Balance at the beginning at Dec. 31, 2022 $ 226,985 $ 15 $ 419,190 $ (10) $ (192,210)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares)   100,587      
Issuance of common stock upon net exercise of stock options 33   33    
Issuance of common stock upon vesting of restricted stock units (in shares)   1,841,257      
Issuance of common stock upon exercise of warrants (in shares)   830,216      
Issuance of common stock upon exercise of warrants 348   348    
Stock-based compensation cost 5,101   5,101    
Cumulative translation adjustment (16)     (16)  
Net loss (28,609)       (28,609)
Balance at the end (in shares) at Mar. 31, 2023   147,977,034      
Balance at the end at Mar. 31, 2023 203,842 $ 15 424,672 (26) (220,819)
Balance at the beginning (in shares) at Dec. 31, 2023   151,310,080      
Balance at the beginning at Dec. 31, 2023 $ 146,323 $ 15 444,825 (53) (298,464)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Issuance of common stock upon net exercise of stock options (in shares) 519,089 519,089      
Issuance of common stock upon net exercise of stock options $ 302 $ 1 301    
Issuance of common stock upon vesting of restricted stock units (in shares)   3,527,778      
Stock-based compensation cost 6,605   6,605    
Cumulative translation adjustment 3     3  
Net loss (11,644)       (11,644)
Balance at the end (in shares) at Mar. 31, 2024   155,356,947      
Balance at the end at Mar. 31, 2024 $ 141,589 $ 16 $ 451,731 $ (50) $ (310,108)